

October 1, 2025

Company name:	ELAN Corporation
Name of representative:	Tomohiro Minezaki, CEO (Securities code: 6099; TSE Prime Market)
Inquiries:	Hideo Hara, Executive Officer, President's Office Manager (Telephone: +81-263-41-0760)

Notice Regarding Listing Approval for Our Equity Method Affiliate (Classico Inc.)

We hereby announce that today, the Tokyo Stock Exchange, Inc. approved the new listing of our equity-method affiliate, Classico Inc. (hereinafter referred to as "Classico"), on the Tokyo Stock Exchange Growth Market.

1. Regarding the Listing of Classico

(1) Positioning of Classico within Our Group

Our company operates the "CS Set," a comprehensive service combining rental with clothing and towel exchange services with the provision of disposable diapers and daily necessities (toothbrushes, tissues, oral care products, etc.) for hospitals, nursing care facilities, and similar institutions.

Based on a capital and business alliance, our company and Classico have long engaged in business exchanges aimed at mutual business development and enhancing corporate value. We procure the original patient clothing "lifte," provided to CS Set users, from Classico.

(2) Purpose of the Listing

Classico specializes in the planning, development, and sale of medical apparel for healthcare professionals working in clinical settings. The company excels in developing medical uniforms that combine beautiful style with functionality. By accurately understanding the needs of healthcare professionals and operating its business to rapidly develop and improve products, Classico has steadily expanded its support among healthcare workers year after year.

The company believes that going public will enhance its social credibility and domestic and international recognition. This will facilitate the expansion of its business partners and the recruitment of talented personnel, thereby contributing to a further increase in corporate value.

(3) Policy on Holding Classico Shares

Even after Classico's listing, the company is expected to remain an equity-method affiliate of our company. We will continue to pursue the growth of our entire group and maximize corporate value. However, as greater independence will be required post-listing, we will increasingly respect Classico's independence and support its autonomous management.

The post-listing shareholding ratio will be determined reasonably, taking into account the relationship between our group and Classico.

2. Overview of Classico

(1) Name	Classico Inc.	
(2) Address	5-12, Akasaka 9-chome, Minato-ku, Tokyo	
(3) Representative	Arata Ohwa, Representative Director and CEO	
(4) Business	Planning, development and sales of medical apparel	
(5) Capital	836,231 thousand yen	
(6) Date of establishment	December 24, 2008	
(7) Major shareholders and shareholding ratio	Arata Ohwa 38.92% ELAN Corporation 33.33%	
(8) Relationship between the listed company and the company	Capital relationship	Our company holds 582,765 shares of Classico common stock.
	Personnel Relationship	One director of the Company concurrently serves as an outside director.
	Business Relationship	The Company purchases original "lifte" patient gowns provided to users of the Company's "CS set" from Classico Inc.

3. Our Group's Approach to Listing Subsidiaries and Other Entities

Our Group aims to expand the overall business value of the Group through the individual development of each Group company, while creating synergies within the Group through mutual complementarity and collaboration.

Regarding the listing of shares of subsidiaries and other entities, we will carefully consider whether such a listing would contribute to enhancing the overall corporate value of our Group, taking into account the business content, management status, and future prospects of the relevant company, before making a decision.

At this time, there are no specific plans for the listing of other subsidiaries or entities.

4. Schedule

(1) Listing Approval Date	October 1,2025
(2) Scheduled Listing Date	November 5,2025

5. Future Outlook

We anticipate that the impact of this matter on our performance for the fiscal year ending December 2025 will be minimal.

Should any matters requiring disclosure arise in the future, we will promptly disclose them.